Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.
Press releases published on April 2, 2025

15.000 Läufer starten mit Leidenschaft beim Jingdong Suqian Marathon 2025
SUQIAN, China, April 02, 2025 (GLOBE NEWSWIRE) -- Am 30. März ist der Startschuss für den Jingdong Suqian Marathon 2025 gefallen. Insgesamt 15.000 Läufer aus aller Welt versammelten sich, um unter der strahlenden Frühlingssonne durch die malerische …

15 000 coureurs participeront avec entrain au marathon de Jingdong Suqian édition 2025
SUQIAN, Chine, 02 avr. 2025 (GLOBE NEWSWIRE) -- Le coup d’envoi du marathon de Jingdong Suqian 2025 a été donné le 30 mars dernier. Au total, 15 000 coureurs venus du monde entier se sont rassemblés pour courir à travers les paysages pittoresques de la …

Prime Biome Reviews DON’T SKIP UNTIL SEE THIS for Preventing Fraud and Guaranteeing Reliability!
ST. PETERSBURG, Fla., April 02, 2025 (GLOBE NEWSWIRE) -- 2025, a popular supplement for reviving the gut and skin micro biota, Prime Biome has swept the wellness industry. Prime Biome is the greatest option for safe, healthy skin out of all the products …

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham …

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (IDE) …

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the …

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases …

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that …

Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: …

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported …

OBLUE Welcomes Two World-Renowned Experts to Expert Endorsement Council
ZHENGZHOU, China, April 02, 2025 (GLOBE NEWSWIRE) -- OBLUE, North America’s premier natural supplement brand, recently announced the appointment of two distinguished experts as its expert endorsers. Professor Ilaria Capua, a member of the Academia Europaea …

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early 2026 Alignment through recent interactions with CDER on path to accelerated approval and conversion to full approval …

Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England …

Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities
Akoya’s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative requires the high plex and high throughput …

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that …

Tri Pointe Homes Named to 2025 Fortune 100 Best Companies to Work For® List, Reflecting the Company’s Commitment to Culture, Innovation, and Empowerment
INCLINE VILLAGE, Nev., April 02, 2025 (GLOBE NEWSWIRE) -- Tri Pointe Homes® (NYSE: TPH), one of the largest homebuilders in the U.S., has once again been named to the Fortune 100 Best Companies to Work For® list, a prestigious recognition compiled by …

MUHC Foundation celebrates $200M Dream Big campaign milestone
MONTREAL, April 02, 2025 (GLOBE NEWSWIRE) -- The McGill University Health Centre (MUHC) Foundation is proud to announce the successful completion of its ambitious Dream Big campaign, which has surpassed its $200 million fundraising goal. Launched in 2020 …

La campagne Oser rêver de la Fondation du CUSM franchit son objectif de 200 millions de dollars
MONTRÉAL, 02 avr. 2025 (GLOBE NEWSWIRE) -- La Fondation du Centre universitaire de santé McGill (CUSM) est fière d’annoncer que son ambitieuse campagne Oser rêver a dépassé son objectif de financement de 200 millions de dollars. Lancée en 2020 durant une …

The Baker Rises Again
SOUTHLAKE, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Thiel …

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, …